Cancer Cytopathology

Cover image for Vol. 122 Issue 10

October 2014

Volume 122, Issue 10

Pages 711–785

  1. CytoSource

    1. Top of page
    2. CytoSource
    3. Cytopathology Help Desk
    4. Editorial
    5. Commentary
    6. Review Article
    7. Original Articles
    1. You have free access to this content
  2. Cytopathology Help Desk

    1. Top of page
    2. CytoSource
    3. Cytopathology Help Desk
    4. Editorial
    5. Commentary
    6. Review Article
    7. Original Articles
  3. Editorial

    1. Top of page
    2. CytoSource
    3. Cytopathology Help Desk
    4. Editorial
    5. Commentary
    6. Review Article
    7. Original Articles
    1. You have free access to this content
      Lessons from early clinical experience with the Afirma gene expression classifier (pages 715–719)

      Jeffrey F. Krane

      Article first published online: 13 AUG 2014 | DOI: 10.1002/cncy.21472

      Early clinical experience with the Afirma gene expression classifier indicates potential limitations of the test in everyday practice. The Afirma test may have diminished utility for Hurthle cell lesions. Additional challenges include high test cost relative to repeat fine needle aspiration and the dependence of test performance on highly variable diagnostic thresholds in cytology and surgical pathology specimens.

  4. Commentary

    1. Top of page
    2. CytoSource
    3. Cytopathology Help Desk
    4. Editorial
    5. Commentary
    6. Review Article
    7. Original Articles
    1. Primary human papillomavirus screening for cervical cancer in the United States—US Food and Drug Administration approval, clinical trials, and where we are today (pages 720–729)

      Ritu Nayar, Robert A. Goulart, Patricia G. Tiscornia-Wasserman and Diane Davis Davey

      Article first published online: 16 SEP 2014 | DOI: 10.1002/cncy.21480

      The US Food and Drug Administration recently approved the additional indication of Primary Screening for the Roche cobas human papillomavirus test. This commentary includes an overview of the supporting clinical trial data, issues this approval will present for laboratorians, and proposed clinical management guidelines for abnormal screening results.

  5. Review Article

    1. Top of page
    2. CytoSource
    3. Cytopathology Help Desk
    4. Editorial
    5. Commentary
    6. Review Article
    7. Original Articles
    1. You have full text access to this OnlineOpen article
      Available resources and challenges for the clinical annotation of somatic variations (pages 730–736)

      Catherine I. Dumur

      Article first published online: 8 AUG 2014 | DOI: 10.1002/cncy.21471

      This review focuses on the publicly available resources for the annotation of somatic variants found by next-generation sequencing (NGS) technologies applied to mutational analyses of tumor specimens in clinical settings. The characteristics of the existing databases as well as the ideal tools needed to comprehensively annotate mutations for the creation of clinically relevant reports for oncology are discussed.

  6. Original Articles

    1. Top of page
    2. CytoSource
    3. Cytopathology Help Desk
    4. Editorial
    5. Commentary
    6. Review Article
    7. Original Articles
    1. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: An institutional experience (pages 737–744)

      Ricardo R. Lastra, Michelle R. Pramick, Cody J. Crammer, Virginia A. LiVolsi and Zubair W. Baloch

      Article first published online: 13 AUG 2014 | DOI: 10.1002/cncy.21455

      A significant number of thyroid fine-needle aspiration cases are diagnosed as indeterminate by cytomorphologic evaluation. The Afirma gene expression classifier test aids in the characterization of these lesions by diagnosing them as benign or suspicious. Herein, the authors report their experience with the use of suspicious Afirma testing in a group of indeterminate thyroid fine-needle aspiration cases.

    2. You have full text access to this OnlineOpen article
      Thyroid fine-needle aspiration cytology: Performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non-GYN Assessment program thyroid fine-needle performance data (pages 745–750)

      Stan G. Eilers, Paula LaPolice, Perkins Mukunyadzi, Umesh Kapur, Amy Wendel Spiczka, Ajay Shah, Husain Saleh, Adebowale Adeniran, Amberly Nunez, Indra Balachandran, Jennifer J. Clark and Larry Lemon

      Article first published online: 9 JUN 2014 | DOI: 10.1002/cncy.21440

      Data from 1558 responses in the American Society for Clinical Pathology Non-GYN Assessment program for thyroid fine-needle aspirates from thyroid neoplasms and malignancies were evaluated for the correct diagnostic interpretation as well as classifying the incorrect responses into treatment-based groups (nonsurgical benign thyroid nodule, thyroid neoplasm, or malignancy). Participants generally performed well, except for the entities of follicular neoplasm and follicular variant of papillary carcinoma, which were challenging diagnoses to program participants.

    3. Molecular characterization of 54 cases of false-negative fine-needle aspiration among 1347 papillary thyroid carcinomas (pages 751–759)

      Agnese Proietti, Nicla Borrelli, Riccardo Giannini, Rossana Romani, Giancarlo Di Coscio, Francesca Quilici, Teresa Rago, Paolo Miccoli, Paolo Vitti and Fulvio Basolo

      Article first published online: 9 JUN 2014 | DOI: 10.1002/cncy.21454

      The rate of false-negative cases on thyroid fine-needle aspiration was 1.3% (18 of 1347 cases) in the referral center. The addition of molecular analysis decreased the false-negative rate to 0.4% (5 of 1347 cases). These data suggest that the addition of BRAF and Ras mutation preoperative assessment may be helpful, but the cost benefit must be carefully evaluated.

    4. p16INK4a overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells (pages 760–769)

      Eric Piaton, Jean-Sébastien Casalegno, Anne-Sophie Advenier, Myriam Decaussin-Petrucci, Florence Mege-Lechevallier, Alain Ruffion and Yahia Mekki

      Article first published online: 28 JUL 2014 | DOI: 10.1002/cncy.21462

      The study shows a low prevalence of oncogenic human papillomaviruses (HPVs) in the urine of patients with high-grade urothelial malignancy. In the tissue sections of tumors, p16INK4a overexpression occurs in the absence of demonstrable HPV DNA, contrary to what is noted in gynecopathology.

    5. Pancreatic neuroendocrine tumors: Accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria (pages 770–778)

      Jessica M. Farrell, Judy C. Pang, Grace E. Kim and Z. Laura Tabatabai

      Article first published online: 9 JUL 2014 | DOI: 10.1002/cncy.21457

      The precise and accurate grading of pancreatic neuroendocrine tumors is critical for predicting biologic behavior patient prognosis, and making informed decisions regarding patient management and treatment. Pancreatic neuroendocrine tumors can be accurately graded by analyzing the Ki-67 proliferation indices in fine-needle aspiration specimens.

    6. You have free access to this content
      Reliability of immunostaining using pan-melanoma cocktail, SOX10, and microphthalmia transcription factor in confirming a diagnosis of melanoma on fine-needle aspiration smears (pages 779–785)

      Jessica Clevenger, Cicily Joseph, Marilyn Dawlett, Ming Guo and Yun Gong

      Article first published online: 20 JUN 2014 | DOI: 10.1002/cncy.21458

      In the current study, SOX10 was found to have the highest detection rate for melanoma on cytology smears, followed by microphthalmia transcription factor (MITF) and pan-melanoma cocktail. The nuclear staining markers, SOX10 and MITF, appear to be more readily interpreted than pan-melanoma cocktail.

SEARCH

SEARCH BY CITATION